News By Tag
News By Location
Ascendis Health announces acquisition of specialist medical devices company RCA for R145 million
Ascendis announced the 100% acquisition of specialist medical devices company Respiratory Care Africa for R 145 million in a cash and shares deal.
RCA is a 15-year old medical device business which distributes and services a range of capital equipment and related surgical consumables, specialising in critical care. They hold key agencies for medical equipment catering to the intensive care unit, neonatal intensive care unit and the operating theatre. The company employs over 100 highly trained staff achieving compound annual revenue growth of circa 18% over the last five years. The business is also well positioned to expand into sub Saharan markets with activities already in Botswana, Namibia, Mozambique, Zimbabwe and Malawi. Sean Reitz, the founder and CEO of RCA, has entered into an employment contract with Ascendis to continue driving the business forward.
RCA is well positioned to take advantage of planned new private hospital builds and expanding requirements in the public sector. They have also been identified as a complementary distributor to the existing medical device division, which will enhance Ascendis’ ability to service hospitals, clinics and government tenders within a growing market.
The acquisition is subject to the regulatory consent of the South African Competition Authorities.
Dr Wellner concludes: “RCA is a strong cash generative business in a market sector with a high barrier to entry offering low volume, high value products with aligned specialist services. We envisage immediate positive benefits through the integration with Surgical Innovations in the fields of procurement, servicing, sales and marketing which could lead to other targeted acquisitions in this sector as we push towards a further improved customer focus by providing turnkey client solutions. RCA is an important milestone for the Pharma Med division and for Ascendis in general as it adds, alongside our strong organic growth, approximately 18% to our published earnings per share for the 6 month period ended 31 December 2013 and thus contributes towards our continued success story.”